The stock of Moderna Inc (NASDAQ:MRNA) last traded at $42.05, down -3.69% from the previous session.
MRNA stock price is now -21.91% away from the 50-day moving average and -56.04% away from the 200-day moving average. The market capitalization of the company currently stands at $16.18B.
With the price target of $42, Berenberg recently initiated with Hold rating for Moderna Inc (NASDAQ: MRNA). On November 18, 2024, HSBC Securities Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $58, while ‘Wolfe Research’ rates the stock as ‘Underperform’
In other news, Hoge Stephen, President sold 277 shares of the company’s stock on Nov 11 ’24. The stock was sold for $12,771 at an average price of $46.10. Upon completion of the transaction, the President now directly owns 1,443,248 shares in the company, valued at $60.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 11 ’24, Officer Hoge Stephen bought 277 shares of the business’s stock. A total of $12,771 was incurred on buying the stock at an average price of $46.10. A total of 10.83% of the company’s stock is owned by insiders.
During the past 12 months, Moderna Inc has had a low of $35.80 and a high of $170.47. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 4.39, and a quick ratio of 4.20. The fifty day moving average price for MRNA is $54.4472 and a two-hundred day moving average price translates $95.888275 for the stock.
The latest earnings results from Moderna Inc (NASDAQ: MRNA) was released for 2024-09-30. The net profit margin was -43.84% and return on equity was -17.52% for MRNA. The company reported revenue of $1.86 billion for the quarter, compared to $1.83 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.69 percent.
